Bispecific Antibody Pretargeting For Improving Cancer Imaging And Therapy
Download Bispecific Antibody Pretargeting For Improving Cancer Imaging And Therapy full books in PDF, epub, and Kindle. Read online free Bispecific Antibody Pretargeting For Improving Cancer Imaging And Therapy ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
| Author | : Elisabeth Eppard |
| Publisher | : BoD – Books on Demand |
| Total Pages | : 156 |
| Release | : 2021-09-29 |
| Genre | : Medical |
| ISBN | : 1839627832 |
In recent years, due to advancing technology and diagnostic and therapeutic techniques, medicine and health care have become more patient-oriented. This concept of personalized medicine or theranostics can be traced back to the beginnings of nuclear medicine when radioisotopes were uncovered as diagnostic and therapeutic tools. Nowadays, the field of theranostics is in flux, as new techniques and materials allow a growing range of applications beneficial for patients. This book examines new developments in theranostics and provides a comprehensive overview of the state of the art in this exciting discipline.
| Author | : Tod W. Speer |
| Publisher | : Lippincott Williams & Wilkins |
| Total Pages | : 564 |
| Release | : 2012-03-28 |
| Genre | : Medical |
| ISBN | : 1451153260 |
Radioimmunotherapy, also known as systemic targeted radiation therapy, uses antibodies, antibody fragments, or compounds as carriers to guide radiation to the targets. It is a topic rapidly increasing in importance and success in treatment of cancer patients. This book represents a comprehensive amalgamation of the radiation physics, chemistry, radiobiology, tumor models, and clinical data for targeted radionuclide therapy. It outlines the current challenges and provides a glimpse at future directions. With significant advances in cell biology and molecular engineering, many targeting constructs are now available that will safely deliver these highly cytotoxic radionuclides in a targeted fashion. A companion website includes the full text and an image bank.
| Author | : Paul G. Abrams |
| Publisher | : CRC Press |
| Total Pages | : 395 |
| Release | : 2000-07-11 |
| Genre | : Medical |
| ISBN | : 0824741927 |
Reflecting the past 20 years of intense research in radioimmunotherapy, this timely reference surveys an expansive breadth of topics on the evolving developments in radiation therapy. Placed in the context of advances in cancer treatment, chapters progress systematically from basic principles and properties of radionuclides to detailed summaries of
| Author | : Torgny Stigbrand |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 407 |
| Release | : 2008-09-01 |
| Genre | : Medical |
| ISBN | : 1402086962 |
The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book “Targeted Radionuclide Tumour Therapy – Biological Aspects” was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.
| Author | : Jennie R. Lill |
| Publisher | : John Wiley & Sons |
| Total Pages | : 378 |
| Release | : 2017-08-14 |
| Genre | : Science |
| ISBN | : 1119053102 |
The definitive guide to the myriad analytical techniques available to scientists involved in biotherapeutics research Analytical Characterization of Biotherapeutics covers all current and emerging analytical tools and techniques used for the characterization of therapeutic proteins and antigen reagents. From basic recombinant antigen and antibody characterization, to complex analyses for increasingly complex molecular designs, the book explores the history of the analysis techniques and offers valuable insights into the most important emerging analytical solutions. In addition, it frames critical questions warranting attention in the design and delivery of a therapeutic protein, exposes analytical challenges that may occur when characterizing these molecules, and presents a number of tested solutions. The first single-volume guide of its kind, Analytical Characterization of Biotherapeutics brings together contributions from scientists at the leading edge of biotherapeutics research and manufacturing. Key topics covered in-depth include the structural characterization of recombinant proteins and antibodies, antibody de novo sequencing, characterization of antibody drug conjugates, characterization of bi-specific or other hybrid molecules, characterization of manufacturing host-cell contaminant proteins, analytical tools for biologics molecular assessment, and more. Each chapter is written by a recognized expert or experts in their field who discuss current and cutting edge approaches to fully characterizing biotherapeutic proteins and antigen reagents Covers the full range of characterization strategies for large molecule based therapeutics Provides an up-to-date account of the latest approaches used for large molecule characterization Chapters cover the background needed to understand the challenges at hand, solutions to characterize these large molecules, and a summary of emerging options for analytical characterization Analytical Characterization of Biotherapeutics is an up-to-date resource for analytical scientists, biologists, and mass spectrometrists involved in the analysis of biomolecules, as well as scientists employed in the pharmaceuticals and biotechnology industries. Graduate students in biology and analytical science, and their instructors will find it to be fascinating and instructive supplementary reading.
| Author | : Marc Damelin |
| Publisher | : Springer |
| Total Pages | : 358 |
| Release | : 2018-05-29 |
| Genre | : Medical |
| ISBN | : 3319781545 |
Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.
| Author | : National Research Council |
| Publisher | : National Academies Press |
| Total Pages | : 173 |
| Release | : 2007-09-11 |
| Genre | : Medical |
| ISBN | : 0309134153 |
Nearly 20 million nuclear medicine procedures are carried out each year in the United States alone to diagnose and treat cancers, cardiovascular disease, and certain neurological disorders. Many of the advancements in nuclear medicine have been the result of research investments made during the past 50 years where these procedures are now a routine part of clinical care. Although nuclear medicine plays an important role in biomedical research and disease management, its promise is only beginning to be realized. Advancing Nuclear Medicine Through Innovation highlights the exciting emerging opportunities in nuclear medicine, which include assessing the efficacy of new drugs in development, individualizing treatment to the patient, and understanding the biology of human diseases. Health care and pharmaceutical professionals will be most interested in this book's examination of the challenges the field faces and its recommendations for ways to reduce these impediments.
| Author | : Eline P. Meulenberg |
| Publisher | : Bentham Science Publishers |
| Total Pages | : 328 |
| Release | : 2012-05-16 |
| Genre | : Medical |
| ISBN | : 1608052648 |
Antibodies Applications and New Developments is an overview of the current developments of techniques and methods relating to immunodiagnostics and immunoanalysis. This eBook also deals with specialties in the fields of drug, pesticide, antigen and food contaminant detection. The volume is useful for professional immunologists and biotechnologists interested in antibody research and development.
| Author | : Stefan R. Schmidt |
| Publisher | : John Wiley & Sons |
| Total Pages | : 995 |
| Release | : 2013-01-28 |
| Genre | : Medical |
| ISBN | : 1118354583 |
The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.
| Author | : Roland E. Kontermann |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 381 |
| Release | : 2011-07-21 |
| Genre | : Medical |
| ISBN | : 3642209106 |
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed several years ago. Initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. The progress in antibody engineering finally led to the generation of new classes of bispecific antibodies lacking these obstacles. In addition, new applications were established, such as pre-targeting strategies in radioimmunotherapy and dual targeting approaches in order to improve binding, selectivity and efficacy. In this book, the different ways of generating bispecific antibodies are described, with emphasis on recombinant formats. The various applications of bispecific antibodies, e.g. in cellular cancer immunotherapy, radioimmunotherapy and pretargeting strategies are covered, and emerging applications such as dual targeting strategies, which involve the simultaneous inhibition of two targets, are addressed.
